Calyxo announced it has raised $40 million in a Series F financing round to support continued growth of its kidney stone treatment platform. The round was led by Ally Bridge Group and Janus Henderson Investors, with participation from Questa Capital, Avidity Partners, and CRG.
The financing follows a key milestone for the company, with more than 40,000 patients treated using its CVAC System, an aspiration-based solution designed to improve kidney stone removal outcomes. The system enables continuous removal of stone fragments, supporting more complete clearance and improved procedural efficiency.
Calyxo will use the new capital to expand its commercial infrastructure, advance clinical and health economic studies, and continue product innovation aimed at improving long-term patient outcomes and reducing downstream healthcare costs.
The CVAC System, which received FDA clearance in 2024, is designed as a minimally invasive, all-in-one solution that combines irrigation and vacuum aspiration to enhance stone removal during procedures.
The company is positioning its technology as a shift toward complete stone clearance as a standard of care, supported by clinical and real-world evidence demonstrating improved outcomes and efficiency.
KEY QUOTES:
“Ally Bridge Group is pleased to lead this financing to support Calyxo’s continued growth. The company is addressing a meaningful need in kidney stone treatment with a differentiated approach supported by strong clinical validation and physician adoption. We are excited to partner with the Calyxo team as they continue to build on this momentum.”
Kevin Reilly, Managing Director And Head Of Medtech, Ally Bridge Group
“This financing marks an important inflection point for Calyxo. More than 40,000 patients have now been treated with the CVAC System. Real-world experience, together with an established body of clinical evidence, indicates that the CVAC System is moving beyond early adoption and becoming an important part of the standard of care in kidney stone treatment. This financing allows us to move faster in advancing our technology and expanding the evidence base to further improve patient care.”
Joe Catanese, Chief Executive Officer, Calyxo
